JP Morgan Chase’s Correvio Pharma Corp. Ordinary Shares (Canada) CORV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-69,947
| Closed | -$27K | – | 5926 |
|
|
2020
Q1 | $27K | Sell |
69,947
-66,422
| -49% | -$24K | ﹤0.01% | 4889 |
|
|
2019
Q4 | $56K | Sell |
136,369
-28,836
| -17% | -$47.9K | ﹤0.01% | 5093 |
|
|
2019
Q3 | $330K | Buy |
165,205
+1,050
| +0.6% | +$2.13K | ﹤0.01% | 4374 |
|
|
2019
Q2 | $369K | Buy |
164,155
+7
| +0% | +$18 | ﹤0.01% | 4375 |
|
|
2019
Q1 | $519K | Sell |
164,148
-66,433
| -29% | -$215K | ﹤0.01% | 4195 |
|
|
2018
Q4 | $574K | Buy |
230,581
+46,828
| +25% | +$156K | ﹤0.01% | 4060 |
|
|
2018
Q3 | $738K | Buy |
183,753
+12,501
| +7% | +$55.1K | ﹤0.01% | 4081 |
|
|
2018
Q2 | $647K | Buy |
171,252
+1,159
| +0.7% | +$3.02K | ﹤0.01% | 4055 |
|
|
2018
Q1 | $395K | Buy |
170,093
+8,643
| +5% | +$13.7K | ﹤0.01% | 4115 |
|
|
2017
Q4 | $250K | Buy |
161,450
+2,753
| +2% | +$4.42K | ﹤0.01% | 4332 |
|
|
2017
Q3 | $329K | Buy |
158,697
+3,602
| +2% | +$12.3K | ﹤0.01% | 3957 |
|
|
2017
Q2 | $701K | Buy |
155,095
+42,416
| +38% | +$154K | ﹤0.01% | 3593 |
|
|
2017
Q1 | $339K | Buy |
112,679
+57,782
| +105% | +$170K | ﹤0.01% | 3866 |
|
|
2016
Q4 | $151K | Buy |
54,897
+49,691
| +954% | +$142K | ﹤0.01% | 4270 |
|
|
2016
Q3 | $16K | Buy |
5,206
+5,204
| +260,200% | +$19K | ﹤0.01% | 4235 |
|
|
2016
Q2 | $0 | Sell |
2
-600
| -100% | -$2.88K | ﹤0.01% | 5077 |
|
|
2016
Q1 | $2K | Buy |
602
+600
| +30,000% | +$3.21K | ﹤0.01% | 4529 |
|
|
2015
Q4 | $0 | Buy |
+2
| New | +$17 | ﹤0.01% | 4866 |
|
JP Morgan Chase's CORV Position: Q2 2020 in Review
JP Morgan Chase sold out of Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) in Q2 2020, closing a stake of 69,947 shares — an estimated $27K sold.
JP Morgan Chase first reported a position in CORV in Q4 2015 and held it in 18 quarters. The position peaked at $738K in Q3 2018. 0 funds tracked by Wall St. Rank hold CORV as of Q2 2020.
- JP Morgan Chase reported no remaining Correvio Pharma Corp. Ordinary Shares (Canada) position as of Q2 2020 after selling out during the quarter.
- JP Morgan Chase sold 69,947 Correvio Pharma Corp. Ordinary Shares (Canada) shares in Q2 2020, an estimated $27K.
- JP Morgan Chase first reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) in Q4 2015 and held it in 18 quarters.
- JP Morgan Chase's Correvio Pharma Corp. Ordinary Shares (Canada) position peaked at $738K in Q3 2018.
- 0 funds tracked by Wall St. Rank held Correvio Pharma Corp. Ordinary Shares (Canada) as of Q2 2020.
Based on JP Morgan Chase's 13F filing for Q2 2020, filed 11 Aug 2020.